SCHEMBL15524422

SCHEMBL15524422

C[C@@H](CO[Si](C)(C)C(C)(C)C)ON1C(=O)c2ccccc2C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.36
MAPT P10636 6/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 5/20 0.35
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 3/20 0.33
HTT P42858 2/20 0.33
HPGD P15428 2/20 0.33
DUT P33316 2/20 0.33
F2 P00734 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
XBP1 P17861 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33
PLA2G1B P04054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2564897 1.00 GAA (0.36) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20346803 0.87 GAA (0.37) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL24307921 0.80 BTN3A1 (0.35) GAAMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL14699971 0.79 PLA2G1B (0.34) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL10448217 0.79 POLB (0.32) SMN1; SMN2POLBLMNAPLA2G1BATG4B
SCHEMBL3971334 0.78 POLB (0.43) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1581269 0.78 POLB (0.43) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1581270 0.78 POLB (0.43) GAAMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL9685262 0.77 POLB (0.32) GAAMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL16443634 0.76 ELANE (0.33) GAAMAPTKMT2ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635587-B1 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS CENTAURUS BIOPHARMA CO LTD (CN) 2017-02-15 EP disclosed
EP-2635587-B1 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS CENTAURUS BIOPHARMA CO LTD (CN) 2017-02-15 EP disclosed
US-9540396-B2 6-arylamino pyridone carboxamide as MEK inhibitors CENTAURUS BIOPHARMA CO., LTD. (CN) 2017-01-10 US disclosed
US-20140080804-A1 NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS CENTAURUS BIOPHARMA CO., LTD. (CN) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080804-A1 NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS MAP3K6, MAP3K1, MAP3K21 GAA 2719/4885MAPT 266/4885MEN1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.